Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 6
1994 3
1995 2
1996 1
1997 3
1998 3
1999 6
2000 4
2001 5
2002 6
2003 5
2004 9
2005 11
2006 12
2007 21
2008 19
2009 21
2010 24
2011 17
2012 19
2013 41
2014 34
2015 37
2016 35
2017 29
2018 34
2019 44
2020 37
2021 54
2022 41
2023 26
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

553 results

Results by year

Filters applied: . Clear all
Page 1
Syndromic Craniosynostosis.
Sawh-Martinez R, Steinbacher DM. Sawh-Martinez R, et al. Clin Plast Surg. 2019 Apr;46(2):141-155. doi: 10.1016/j.cps.2018.11.009. Clin Plast Surg. 2019. PMID: 30851747 Review.
The most common craniosynostosis syndromes include Apert (FGFR2), Crouzon (FGFR2), Muenke (FGFR3), Pfeiffer (FGFR1 and FGFR2), and Saethre-Chotzen (TWIST). Bicoronal craniosynostosis (turribrachycephaly) is most commonly associated with syndromic craniosynostosis. ...
The most common craniosynostosis syndromes include Apert (FGFR2), Crouzon (FGFR2), Muenke (FGFR3), Pfeiffer (FGFR1 and FGFR2), and Sa …
Updates on eosinophilic disorders.
Tzankov A, Reichard KK, Hasserjian RP, Arber DA, Orazi A, Wang SA. Tzankov A, et al. Virchows Arch. 2023 Jan;482(1):85-97. doi: 10.1007/s00428-022-03402-8. Epub 2022 Sep 7. Virchows Arch. 2023. PMID: 36068374 Review.
This review addresses changes and updates in eosinophilic disorders under the International Consensus Classification (ICC). ...The updated understanding of the clinical and molecular genetic features of PDGFRA, PDGFRB and FGFR1 neoplasms is summarized. Clear guidanc …
This review addresses changes and updates in eosinophilic disorders under the International Consensus Classification (ICC). ...The up …
Tumor-induced Osteomalacia: A Comprehensive Review.
Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, Pepe J, Cipriani C, Thakker RV. Minisola S, et al. Endocr Rev. 2023 Mar 4;44(2):323-353. doi: 10.1210/endrev/bnac026. Endocr Rev. 2023. PMID: 36327295 Review.
Phosphaturic mesenchymal tumors are the pathological entities underlying TIO in most affected patients. There is now evidence that FN1-FGFR1 and FN1-FGF1 fusion genes are present in about half of tumors causing this paraneoplastic syndrome. ...
Phosphaturic mesenchymal tumors are the pathological entities underlying TIO in most affected patients. There is now evidence that FN1-FG …
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.
Geng L, Lam KSL, Xu A. Geng L, et al. Nat Rev Endocrinol. 2020 Nov;16(11):654-667. doi: 10.1038/s41574-020-0386-0. Epub 2020 Aug 6. Nat Rev Endocrinol. 2020. PMID: 32764725 Review.
Fibroblast growth factor 21 (FGF21) is a stress-inducible hormone that has important roles in regulating energy balance and glucose and lipid homeostasis through a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and beta-klotho. Administration of FGF21 to …
Fibroblast growth factor 21 (FGF21) is a stress-inducible hormone that has important roles in regulating energy balance and glucose and lipi …
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H. Katoh M, et al. Med Res Rev. 2014 Mar;34(2):280-300. doi: 10.1002/med.21288. Epub 2013 May 21. Med Res Rev. 2014. PMID: 23696246 Review.
Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in multiple myeloma and peripheral T-cell lymphoma. FGFR1 and FGFR3 genes are fused to neighboring TACC1 and TACC3 genes, respectively, due …
Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in mul …
Targeting FGFR inhibition in cholangiocarcinoma.
Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Goyal L, et al. Cancer Treat Rev. 2021 Apr;95:102170. doi: 10.1016/j.ctrv.2021.102170. Epub 2021 Feb 26. Cancer Treat Rev. 2021. PMID: 33735689 Free article. Review.
Current FGFR kinase inhibitors show differences in their structure, mechanisms of target engagement, and specificities for FGFR1, 2, 3 and 4 and other related kinases. These agents offer the potential to improve outcomes in FGFR-driven CCA, and the impact of variations in …
Current FGFR kinase inhibitors show differences in their structure, mechanisms of target engagement, and specificities for FGFR1, 2, …
Philadelphia chromosome-like acute lymphoblastic leukemia.
Tasian SK, Loh ML, Hunger SP. Tasian SK, et al. Blood. 2017 Nov 9;130(19):2064-2072. doi: 10.1182/blood-2017-06-743252. Epub 2017 Oct 2. Blood. 2017. PMID: 28972016 Free PMC article. Review.
Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH, FGFR1, IL2RB, LYN, NTRK3, PDGFRA, PTK2B, TYK2, and the RAS signaling pathway. ...
Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH, FGFR1, IL2RB, LYN, NTRK3, PDGFRA, PTK2B, …
FGF21 in obesity and cancer: New insights.
Lu W, Li X, Luo Y. Lu W, et al. Cancer Lett. 2021 Feb 28;499:5-13. doi: 10.1016/j.canlet.2020.11.026. Epub 2020 Nov 29. Cancer Lett. 2021. PMID: 33264641 Free PMC article. Review.
The white and brown adipose tissues and, to some extent, the hypothalamus, all of which host a transmembrane receptor binary complex of FGFR1 and co-receptor KLB, are considered the essential tissue and molecular targets of hepatic or pharmacological FGF21. ...Beyond regul …
The white and brown adipose tissues and, to some extent, the hypothalamus, all of which host a transmembrane receptor binary complex of F …
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M. Katoh M. Int J Mol Med. 2016 Jul;38(1):3-15. doi: 10.3892/ijmm.2016.2620. Epub 2016 May 31. Int J Mol Med. 2016. PMID: 27245147 Free PMC article. Review.
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FGFR kinases, whereas FGFR1-TACC1, FGFR2-AFF3, FGFR2-BICC1, FGFR2-PPHLN1, FGFR3-BAIAP2L1 …
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myelopr …
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. Kohno T, et al. Transl Lung Cancer Res. 2015 Apr;4(2):156-64. doi: 10.3978/j.issn.2218-6751.2014.11.11. Transl Lung Cancer Res. 2015. PMID: 25870798 Free PMC article. Review.
Accordingly, there are several ongoing clinical trials aimed at examining the efficacy of tyrosine kinase inhibitors (TKIs) against RET and ROS1 proteins in patients with fusion-positive lung cancer. Other gene fusions (NTRK1, NRG1, and FGFR1/2/3) that are targetable by ex …
Accordingly, there are several ongoing clinical trials aimed at examining the efficacy of tyrosine kinase inhibitors (TKIs) against RET and …
553 results